NEW DRUG-ELUTING STENTS WHICH ENABLE SPEEDY RECOVERY.
Drug-Eluting Stents (DES) have consistently been shown to reduce the risk of re-narrowing of blood vessel and repeat intervention as compared to Bare Metal Stems (BMS). Dr. Rajasekhar Varada, Senior Consultant, Interventional Cardiology and Electrophysiology, Yashoda Hospital , Secunderabad, speaks about how clot formation in stent emerged as a major safety concern with first generation DES after their adoption in clinical practice, which required prolonged dual antiplatelet therapy. Pathological studies have shown that first-generation DES are also associated with delayed arterial healing and long-term durable polymer exposure. The mechanisms underlying clot formation in stents are multi-factorial and include patient-related factors, procedural factors (including stent choice), and post-procedural factors (including type and duration of anti-platelet therapy). Many strategies can reduce the occurrence of clot formation in stent, including the choice of DES implanted. New generation DES have been developed to overcome these issues with improved stent designs and the use of bio-absorbable polymers coating, giving interventional cardiologists more options while taking care of cardiovascular patients. The Synergy Stent System is the only FDA approved bio-absorbable polymer stent commercially available today, which is designed to help patients heal from day one. The Synergy Stent features ultra-thin struts (74 microns) with a synchronous bio-absorbable polymer coating on the abluminal side of the stent. The polymer goes when it's not needed shortly after the drug is completely eluted at three months, which minimises polymer exposure in the vessel. This allows the stent to be a much more effective vehicle for minimising chances of re-narrowing of artery and faster healing. The technology offers the benefits of being able to improve the ability to acutely treat patients, improves the vessel's ability to heal, reduces the probability of late adverse events and frees patients from long-term polymer exposure. Dr. Rajasekhar Varada said, "In a very complex group of 100 patients, the Synergy Stent showed 0% clot formation at 12-months despite 77% of the patients discontinuing dual anti-platelet therapy at 3 months, as revealed during TCT2015".
[Based on an article written by Dr. Rajasekhar Varada, published in The Times of India, dated 05th March, 2016 (Saturday)].
-Challapalli Srinivas Chakravarthy, 10th February, 2019-
-----------------------------------------------------------------
Comments
Post a Comment